Companies Mersana Therapeutics
Mersana Therapeutics (MRSN): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Mersana Therapeutics’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers26th pct.Of 23 peer CEOs
CEO pay, last three years
- $2,601,249FY2023
- $1,613,754FY2024
CEO total pay was $1,613,754 in fiscal 2024, down from $2,601,249 in fiscal 2023.
FY2024: salary $632,500 · bonus $0 · stock awards $133,635 · option awards $518,044
Executives and directors
Alejandra Carvajal · General CounselBrian DeSchuytner · CFOMichael Huber · CEOMohan Bala · ExecutiveTimothy Lowinger · SVPAllene M. Diaz · Independent DirectorAndrew A. F. Hack, M.D., Ph.D · Independent DirectorAnna Protopapas · Independent DirectorDavid Mott · Chair of the BoardKristen M. Hege, M.D · Independent DirectorLawrence M. Alleva · Independent DirectorMartin Huber, M.D · DirectorWillard Dere, M.D · Independent Director
Frequently asked questions
Who was the highest-paid executive at Mersana Therapeutics in fiscal 2024?
As disclosed, Michael Huber (President and Chief Executive Officer) was the highest-paid executive at Mersana Therapeutics in fiscal 2024, with total compensation of $1,613,754.
How does Mersana Therapeutics's chief executive pay compare to its disclosed peer group?
As disclosed, Michael Huber's total compensation ranked at the 26th percentile of Mersana Therapeutics's disclosed peer group.
What is Mersana Therapeutics's CEO-to-median employee pay ratio?
As disclosed, Mersana Therapeutics's CEO-to-median employee pay ratio was 5:1.
How much does Mersana Therapeutics spend in total on board compensation for fiscal 2024?
As disclosed, Mersana Therapeutics reported total board compensation of $376,000 for fiscal 2024.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Michael Huber | $632,500 | $0 | $133,635 | $518,044 | $322,575 | $0 | $7,000 | $1,613,754 |
| President and Chief Executive Officer | ||||||||
| Brian DeSchuytner | 500,000 | 0 | 176,166 | 682,920 | 177,500 | 0 | 7,000 | 1,543,586 |
| Senior Vice President, Chief Operating Officer and Chief Financial Officer | ||||||||
| Mohan Bala | 470,000 | 0 | 176,166 | 682,920 | 166,850 | 0 | 7,000 | 1,502,936 |
| Senior Vice President, Chief Development Officer | ||||||||
| Timothy Lowinger | 485,000 | 0 | 151,000 | 585,360 | 172,175 | 0 | 7,000 | 1,400,535 |
| Senior Vice President, Chief Science and Technology Officer | ||||||||
| Alejandra Carvajal | 455,000 | 0 | 151,000 | 585,360 | 161,525 | 0 | 7,000 | 1,359,885 |
| Senior Vice President, Chief Legal Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Michael Huber | $1,613,754 | $2,601,249 | — | ↓ −987,495 |
| Brian DeSchuytner | 1,543,586 | 1,738,215 | 1,297,485 | ↓ −194,629 |
| Mohan Bala | 1,502,936 | 1,581,334 | 874,978 | ↓ −78,398 |
| Timothy Lowinger | 1,400,535 | 1,689,068 | 1,180,869 | ↓ −288,533 |
| Alejandra Carvajal | 1,359,885 | 1,613,231 | 874,978 | ↓ −253,346 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program is designed to attract, retain and reward talented executives, to incentivize them based on the achievement of key performance goals, and to align their interests with the interests of our stockholders. We intend for total compensation to be competitive in the biopharmaceutical marketplace, with a majority of compensation provided in long-term equity incentives to focus executives on long-term success.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer & Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2024
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Brian DeSchuytner | OPTION | 2024-01-15 | — | — | 262,500 | — | $682,920 |
| Mohan Bala | RSU | 2024-01-15 | — | — | 58,333 | — | 176,166 |
| Alejandra Carvajal | RSU | 2024-01-15 | — | — | 50,000 | — | 151,000 |
| Michael Huber | RSU | 2024-01-15 | — | — | 44,250 | — | 133,635 |
| Timothy Lowinger | RSU | 2024-01-15 | — | — | 50,000 | — | 151,000 |
| Brian DeSchuytner | RSU | 2024-01-15 | — | — | 58,333 | — | 176,166 |
| Alejandra Carvajal | OPTION | 2024-01-15 | — | — | 225,000 | — | 585,360 |
| Timothy Lowinger | OPTION | 2024-01-15 | — | — | 225,000 | — | 585,360 |
| Michael Huber | OPTION | 2024-01-15 | — | — | 199,125 | — | 518,044 |
| Mohan Bala | OPTION | 2024-01-15 | — | — | 262,500 | — | 682,920 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Brian DeSchuytner | $176,166 | $0 | $682,920 | 0.0% |
| Mohan Bala | 176,166 | 0 | 682,920 | 0.0% |
| Alejandra Carvajal | 151,000 | 0 | 585,360 | 0.0% |
| Michael Huber | 133,635 | 0 | 518,044 | 0.0% |
| Timothy Lowinger | 151,000 | 0 | 585,360 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Alejandra Carvajal | RSU | 5,000 | — | $7,150 |
| Brian DeSchuytner | RSU | 6,250 | — | 8,938 |
| Mohan Bala | RSU | 6,250 | — | 8,938 |
| Brian DeSchuytner | Option | 7,032 | 21.09 | — |
| Timothy Lowinger | RSU | 7,291 | — | 10,426 |
| Timothy Lowinger | Option | 8,204 | 21.09 | — |
| Timothy Lowinger | RSU | 9,583 | — | 13,704 |
| Brian DeSchuytner | RSU | 12,500 | — | 17,875 |
| Alejandra Carvajal | Option | 14,062 | 6.28 | — |
| Alejandra Carvajal | Option | 14,062 | 16.98 | — |
| Mohan Bala | RSU | 26,250 | — | 37,538 |
| Alejandra Carvajal | RSU | 26,875 | — | 38,431 |
| Timothy Lowinger | Option | 26,954 | 6.28 | — |
| Timothy Lowinger | RSU | 28,125 | — | 40,219 |
| Mohan Bala | Option | 28,125 | 8.63 | — |
| Brian DeSchuytner | RSU | 30,000 | — | 42,900 |
| Brian DeSchuytner | Option | 35,157 | 6.28 | — |
| Michael Huber | RSU | 44,250 | — | 63,278 |
| Alejandra Carvajal | RSU | 50,000 | — | 71,500 |
| Timothy Lowinger | RSU | 50,000 | — | 71,500 |
| Brian DeSchuytner | RSU | 58,333 | — | 83,416 |
| Mohan Bala | RSU | 58,333 | — | 83,416 |
| Mohan Bala | Option | 88,594 | 6.06 | — |
| Alejandra Carvajal | Option | 90,703 | 6.06 | — |
| Timothy Lowinger | Option | 94,922 | 6.06 | — |
| Brian DeSchuytner | Option | 101,250 | 6.06 | — |
| Michael Huber | Option | 161,789 | 3.02 | — |
| Alejandra Carvajal | Option | 182,812 | 3.02 | — |
| Timothy Lowinger | Option | 182,812 | 3.02 | — |
| Brian DeSchuytner | Option | 213,281 | 3.02 | — |
| Mohan Bala | Option | 213,281 | 3.02 | — |
| Michael Huber | RSU | 500,250 | — | 715,358 |
| Michael Huber | Option | 687,500 | 1.32 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| David MottIndependent · Board Chair · Compensation Committee (Chair) | $80,000 | — | $105,996 | — | — | $185,996 |
| Lawrence M. AllevaIndependent · Audit Committee (Chair) · Nominating and Corporate Governance Committee | 59,000 | — | 105,996 | — | — | 164,996 |
| Willard Dere, M.DIndependent · Audit | 55,500 | — | 105,996 | — | — | 161,496 |
| Kristen M. Hege, M.DIndependent · Compensation | 49,000 | — | 105,996 | — | — | 154,996 |
| Andrew A. F. Hack, M.D., Ph.DIndependent · Audit | 47,500 | — | 105,996 | — | — | 153,496 |
| Allene M. DiazIndependent · Audit Committee · Compensation Committee · Partial-year service | 45,000 | — | 105,996 | — | — | 150,996 |
| Anna ProtopapasNot independent · Partial-year service | 40,000 | — | 105,996 | — | — | 145,996 |
| Martin Huber, M.DEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $105,996 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | Set robust executive officer and non-employee director stock ownership guidelines |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $376,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $376,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Mersana Therapeutics as a peer
Companies that benchmark against MRSN
12 companies name MRSN as a compensation peer
The list of companies that name MRSN as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2024
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
IPSC Century Therapeutics, Inc.OMGA Omega Therapeutics, Inc.VSTM Verastem, Inc.ZYME Zymeworks, Inc.FHTX Foghorn Therapeutics, Inc.ITOS iTeos Therapeutics, Inc.BDTX Black Diamond Therapeutics, Inc.PRLD Prelude Therapeutics IncorporatedACET Adicet Bio, Inc.CCCC C4 Therapeutics, Inc.IGMS IGM Biosciences, Inc.INO Inovio Pharmaceuticals, Inc.GLUE Monte Rosa Therapeutics, Inc.TNGX Tango Therapeutics, Inc.TCRX TScan Therapeutics, Inc.VOR Vor Biopharma, Inc.HOWL Werewolf Therapeutics, Inc.IKNA Ikena Oncology, Inc.SRRK Scholar Rock Holding CorporationCUE Cue Biopharma, Inc.CTMX CytomX Therapeutics, Inc.FATE Fate Therapeutics, Inc.PYXS Pyxis Oncology, Inc.
Peer reciprocity
The companies Mersana Therapeutics names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Vor Biopharma, Inc. | 2025 | Jean-Paul Kress | $344,615 | $0 | $64,013,465 | $251,425 | $65,027,569 |
| 2 | Scholar Rock Holding Corporation | 2025 | David Hallal | 637,500 | 22,518,500 | 7,624,988 | 452,293 | 33,300,927 |
| 3 | Zymeworks, Inc. | 2025 | Kenneth Galbraith | 656,763 | 2,538,240 | 2,366,565 | 340,990 | 6,613,180 |
| 4 | iTeos Therapeutics, Inc. | 2024 | Michel Detheux | 628,684 | 0 | 4,965,264 | 421,014 | 6,085,657 |
| 5 | Monte Rosa Therapeutics, Inc. | 2025 | Markus Warmuth | 650,000 | 910,080 | 3,043,648 | 429,000 | 5,032,728 |
| 6 | CytomX Therapeutics, Inc. | 2025 | Sean McCarthy | 675,290 | 1,150,463 | 2,158,170 | 749,572 | 4,738,495 |
| 7 | IGM Biosciences, Inc. | 2023 | Fred Schwarzer | 646,797 | 868,050 | 1,336,743 | 355,738 | 3,207,328 |
| 8 | C4 Therapeutics, Inc. | 2025 | Andrew Hirsch | 694,925 | 710,730 | 848,007 | 573,313 | 2,940,975 |
| 9 | Tango Therapeutics, Inc. | 2025 | Barbara Weber | 697,950 | 308,096 | 1,275,328 | 524,250 | 2,823,992 |
| 10 | TScan Therapeutics, Inc. | 2025 | Gavin MacBeath | 665,000 | 0 | 1,982,800 | 139,650 | 2,801,450 |
| 11 | Werewolf Therapeutics, Inc. | 2024 | Daniel Hicklin | 608,237 | 0 | 1,559,867 | 0 | 2,545,599 |
| 12 | Foghorn Therapeutics, Inc. | 2025 | Adrian Gottschalk | 638,000 | 0 | 1,334,037 | 385,990 | 2,361,027 |
| 13 | Verastem, Inc. | 2025 | Daniel Paterson | 674,000 | 1,161,661 | 0 | 489,324 | 2,349,975 |
| 14 | Fate Therapeutics, Inc. | 2025 | Bahram Valamehr | 600,000 | 0 | 1,283,868 | 360,000 | 2,248,568 |
| 15 | Black Diamond Therapeutics, Inc. | 2025 | Mark Velleca | 667,400 | 189,000 | 1,006,030 | 348,717 | 2,234,919 |
| 16 | Mersana Therapeutics | 2024 | Michael Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
| 17 | Inovio Pharmaceuticals, Inc. | 2025 | Jacqueline Shea | 728,000 | 346,101 | 351,955 | 144,144 | 1,587,155 |
| 18 | Adicet Bio, Inc. | 2025 | Chen Schor | 646,294 | 0 | 512,079 | 284,592 | 1,465,747 |
| 19 | Prelude Therapeutics Incorporated | 2025 | Krishna Vaddi | 615,441 | 0 | 412,744 | 309,465 | 1,348,000 |
| 20 | Cue Biopharma, Inc. | 2025 | Usman Azam | 143,077 | 0 | 1,042,313 | 0 | 1,185,639 |
| 21 | Century Therapeutics, Inc. | 2025 | Gregory Russotti | 559,650 | 71,120 | 51,240 | 226,658 | 912,320 |
| — | Omega Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Ikena Oncology, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Pyxis Oncology, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Mersana Therapeutics | not disclosed | Option 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| Adicet Bio, Inc. | not disclosed | not disclosed | not disclosed | Aon Consulting, Inc. |
| Black Diamond Therapeutics, Inc. | 95% | not disclosed | not disclosed | Aon Human Capital Solutions (Aon plc) |
| C4 Therapeutics, Inc. | 120% | not disclosed | not disclosed | Pearl Meyer |
| Century Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Cue Biopharma, Inc. | not disclosed | Option 100 | not disclosed | Radford, an AON Hewitt company |
| CytomX Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Fate Therapeutics, Inc. | 100% | Options 100 | No | Aon's Human Capital Solutions practice (Radford) |
| Foghorn Therapeutics, Inc. | not disclosed | Options 100 | not disclosed | Pay Governance, LLC |
| IGM Biosciences, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Ikena Oncology, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Inovio Pharmaceuticals, Inc. | 33% | not disclosed | Yes — Relative TSR | Aon (Human Capital Solutions practice) |
| iTeos Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Radford |
| Monte Rosa Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Radford, an Aon Hewitt Company |
| Omega Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Prelude Therapeutics Incorporated | not disclosed | Option 100 | not disclosed | Compensia |
| Pyxis Oncology, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Scholar Rock Holding Corporation | not disclosed | not disclosed | No | Pay Governance |
| Tango Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| TScan Therapeutics, Inc. | not disclosed | Options 100 | not disclosed | not disclosed |
| Verastem, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| Vor Biopharma, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Werewolf Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Pearl Meyer & Partners, LLC |
| Zymeworks, Inc. | not disclosed | Option 50 · RSU 50 | not disclosed | Aon plc (Talent Solutions practice) |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
CEO pay ratio
| Ratio (CEO : median employee) | 5 : 1 |
|---|---|
| CEO total compensation | $1,613,754 |
| Median employee compensation | $316,460 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| David Mott | Director | 2026-01-06 | D | 788 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Mott | Director | 2026-01-06 | D | 1,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Lowinger | SVP, Chief Sci.&Tech. Officer | 2026-01-06 | D | 419 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Lowinger | SVP, Chief Sci.&Tech. Officer | 2026-01-06 | D | 713 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Mott | Director | 2026-01-06 | D | 1,011 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-01-06 | D | 166 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-01-06 | D | 5,227 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-01-06 | D | 1,131 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-01-06 | D | 11,250 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-01-06 | D | 9,043 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-01-06 | D | 665 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ashish Mandelia | VP, Chief Accounting Officer | 2026-01-06 | D | 1,842 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ashish Mandelia | VP, Chief Accounting Officer | 2026-01-06 | D | 310 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ashish Mandelia | VP, Chief Accounting Officer | 2026-01-06 | D | 44 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence M. Alleva | Director | 2026-01-06 | D | 500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence M. Alleva | Director | 2026-01-06 | D | 384 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ashish Mandelia | VP, Chief Accounting Officer | 2026-01-06 | D | 1,312 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ashish Mandelia | VP, Chief Accounting Officer | 2026-01-06 | D | 1,687 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Huber | Director | 2026-01-06 | D | 7,467 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence M. Alleva | Director | 2026-01-06 | D | 159 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence M. Alleva | Director | 2026-01-06 | D | 561 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mohan Bala | SVP, Chief Development | 2026-01-06 | D | 5,246 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence M. Alleva | Director | 2026-01-06 | D | 215 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mohan Bala | SVP, Chief Development | 2026-01-06 | D | 7,734 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mohan Bala | SVP, Chief Development | 2026-01-06 | D | 3,515 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alejandra Carvajal | SVP, Chief Legal Officer | 2026-01-06 | D | 7,921 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alejandra Carvajal | SVP, Chief Legal Officer | 2026-01-06 | D | 1,078 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alejandra Carvajal | SVP, Chief Legal Officer | 2026-01-06 | D | 4,922 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Willard H. Dere | Director | 2026-01-06 | D | 2,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Willard H. Dere | Director | 2026-01-06 | D | 734 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Willard H. Dere | Director | 2026-01-06 | D | 1,800 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Willard H. Dere | Director | 2026-01-06 | D | 513 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Willard H. Dere | Director | 2026-01-06 | D | 1,002 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Willard H. Dere | Director | 2026-01-06 | D | 125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Willard H. Dere | Director | 2026-01-06 | D | 450 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Willard H. Dere | Director | 2026-01-06 | D | 1,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Willard H. Dere | Director | 2026-01-06 | D | 544 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Willard H. Dere | Director | 2026-01-06 | D | 800 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Allene M. Diaz | Director | 2026-01-06 | D | 2,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kristen Hege | Director | 2026-01-06 | D | 2,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kristen Hege | Director | 2026-01-06 | D | 138 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kristen Hege | Director | 2026-01-06 | D | 1,800 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kristen Hege | Director | 2026-01-06 | D | 416 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kristen Hege | Director | 2026-01-06 | D | 1,002 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kristen Hege | Director | 2026-01-06 | D | 101 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kristen Hege | Director | 2026-01-06 | D | 368 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hack Andrew A. F. | Director | 2026-01-06 | D | 2,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hack Andrew A. F. | Director | 2026-01-06 | D | 734 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hack Andrew A. F. | Director | 2026-01-06 | D | 1,800 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hack Andrew A. F. | Director | 2026-01-06 | D | 439 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hack Andrew A. F. | Director | 2026-01-06 | D | 1,002 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian DeSchuytner | SVP, COO & CFO | 2026-01-06 | D | 800 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Lowinger | SVP, Chief Sci.&Tech. Officer | 2026-01-06 | D | 750 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Lowinger | SVP, Chief Sci.&Tech. Officer | 2026-01-06 | D | 3,090 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Lowinger | SVP, Chief Sci.&Tech. Officer | 2026-01-06 | D | 10,466 | — | — | Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-01-06 | D | 2,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ashish Mandelia | VP, Chief Accounting Officer | 2026-01-06 | D | 773 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ashish Mandelia | VP, Chief Accounting Officer | 2026-01-06 | D | 2,300 | — | — | Common | Form 4 ↗ |
| Michael Huber | Director | 2026-01-06 | D | 364 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence M. Alleva | Director | 2026-01-06 | D | 800 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alejandra Carvajal | SVP, Chief Legal Officer | 2026-01-06 | D | 3,047 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Willard H. Dere | Director | 2026-01-06 | D | 2,460 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kristen Hege | Director | 2026-01-06 | D | 1,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kristen Hege | Director | 2026-01-06 | D | 400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hack Andrew A. F. | Director | 2026-01-06 | D | 578 | — | — | Common | Form 4 ↗ |
| Mohan Bala | SVP, Chief Development | 2026-01-06 | D | 2,646 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Willard H. Dere | Director | 2026-01-06 | D | 368 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hack Andrew A. F. | Director | 2026-01-06 | D | 2,088 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian DeSchuytner | SVP, COO & CFO | 2026-01-06 | D | 281 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian DeSchuytner | SVP, COO & CFO | 2026-01-06 | D | 250 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian DeSchuytner | SVP, COO & CFO | 2026-01-06 | D | 6,381 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian DeSchuytner | SVP, COO & CFO | 2026-01-06 | D | 818 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian DeSchuytner | SVP, COO & CFO | 2026-01-06 | D | 327 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian DeSchuytner | SVP, COO & CFO | 2026-01-06 | D | 178 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian DeSchuytner | SVP, COO & CFO | 2026-01-06 | D | 4,009 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Mott | Director | 2026-01-06 | D | 740 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Lowinger | SVP, Chief Sci.&Tech. Officer | 2026-01-06 | D | 1,834 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-01-06 | D | 9,609 | — | — | Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-01-06 | D | 6,721 | — | — | Common | Form 4 ↗ |
| Ashish Mandelia | VP, Chief Accounting Officer | 2026-01-06 | D | 212 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ashish Mandelia | VP, Chief Accounting Officer | 2026-01-06 | D | 555 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Huber | Director | 2026-01-06 | D | 7,256 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Huber | Director | 2026-01-06 | D | 13,340 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Huber | Director | 2026-01-06 | D | 497 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Huber | Director | 2026-01-06 | D | 27,878 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Huber | Director | 2026-01-06 | D | 1,002 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Huber | Director | 2026-01-06 | D | 1,923 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Huber | Director | 2026-01-06 | D | 5,938 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence M. Alleva | Director | 2026-01-06 | D | 2,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence M. Alleva | Director | 2026-01-06 | D | 310 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence M. Alleva | Director | 2026-01-06 | D | 368 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence M. Alleva | Director | 2026-01-06 | D | 450 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence M. Alleva | Director | 2026-01-06 | D | 1,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ashish Mandelia | VP, Chief Accounting Officer | 2026-01-06 | D | 722 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence M. Alleva | Director | 2026-01-06 | D | 142 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence M. Alleva | Director | 2026-01-06 | D | 2,460 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ashish Mandelia | VP, Chief Accounting Officer | 2026-01-06 | D | 788 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ashish Mandelia | VP, Chief Accounting Officer | 2026-01-06 | D | 359 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mohan Bala | SVP, Chief Development | 2026-01-06 | D | 2,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mohan Bala | SVP, Chief Development | 2026-01-06 | D | 1,750 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mohan Bala | SVP, Chief Development | 2026-01-06 | D | 1,853 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kristen Hege | Director | 2026-01-06 | D | 450 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kristen Hege | Director | 2026-01-06 | D | 578 | — | — | Common | Form 4 ↗ |
| Willard H. Dere | Director | 2026-01-06 | D | 1,567 | — | — | Common | Form 4 ↗ |
| Allene M. Diaz | Director | 2026-01-06 | D | 734 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Allene M. Diaz | Director | 2026-01-06 | D | 416 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Allene M. Diaz | Director | 2026-01-06 | D | 1,571 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Allene M. Diaz | Director | 2026-01-06 | D | 2,460 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Allene M. Diaz | Director | 2026-01-06 | D | 578 | — | — | Common | Form 4 ↗ |
| Kristen Hege | Director | 2026-01-06 | D | 257 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kristen Hege | Director | 2026-01-06 | D | 380 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian DeSchuytner | SVP, COO & CFO | 2026-01-06 | D | 9,422 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hack Andrew A. F. | Director | 2026-01-06 | D | 2,460 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Lowinger | SVP, Chief Sci.&Tech. Officer | 2026-01-06 | D | 1,040 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Lowinger | SVP, Chief Sci.&Tech. Officer | 2026-01-06 | D | 3,234 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Lowinger | SVP, Chief Sci.&Tech. Officer | 2026-01-06 | D | 215 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Lowinger | SVP, Chief Sci.&Tech. Officer | 2026-01-06 | D | 1,578 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Lowinger | SVP, Chief Sci.&Tech. Officer | 2026-01-06 | D | 696 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Lowinger | SVP, Chief Sci.&Tech. Officer | 2026-01-06 | D | 6,702 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-01-06 | D | 11,761 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-01-06 | D | 988 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-01-06 | D | 1 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-01-06 | D | 542 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-01-06 | D | 2,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-01-06 | D | 2,460 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alejandra Carvajal | SVP, Chief Legal Officer | 2026-01-06 | D | 1,800 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alejandra Carvajal | SVP, Chief Legal Officer | 2026-01-06 | D | 6,702 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Mott | Director | 2026-01-06 | D | 2,460 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ashish Mandelia | VP, Chief Accounting Officer | 2026-01-06 | D | 2,870 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Huber | Director | 2026-01-06 | D | 12,121 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Huber | Director | 2026-01-06 | D | 1,800 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mohan Bala | SVP, Chief Development | 2026-01-06 | D | 9,309 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kristen Hege | Director | 2026-01-06 | D | 142 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian DeSchuytner | SVP, COO & CFO | 2026-01-06 | D | 4,218 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian DeSchuytner | SVP, COO & CFO | 2026-01-06 | D | 5,590 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian DeSchuytner | SVP, COO & CFO | 2026-01-06 | D | 7,734 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian DeSchuytner | SVP, COO & CFO | 2026-01-06 | D | 5,015 | — | — | Common | Form 4 ↗ |
| David Mott | Director | 2026-01-06 | D | 1,800 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Mott | Director | 2026-01-06 | D | 1,002 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Mott | Director | 2026-01-06 | D | 264 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Mott | Director | 2026-01-06 | D | 383 | — | — | Common, indirect | Form 4 ↗ |
| David Mott | Director | 2026-01-06 | D | 23,546 | — | — | Common | Form 4 ↗ |
| Timothy Lowinger | SVP, Chief Sci.&Tech. Officer | 2026-01-06 | D | 2,166 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Lowinger | SVP, Chief Sci.&Tech. Officer | 2026-01-06 | D | 192 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-01-06 | D | 480 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-01-06 | D | 2,890 | — | — | Common | Form 4 ↗ |
| Ashish Mandelia | VP, Chief Accounting Officer | 2026-01-06 | D | 666 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ashish Mandelia | VP, Chief Accounting Officer | 2026-01-06 | D | 500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ashish Mandelia | VP, Chief Accounting Officer | 2026-01-06 | D | 192 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Huber | Director | 2026-01-06 | D | 1,328 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Huber | Director | 2026-01-06 | D | 179 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Huber | Director | 2026-01-06 | D | 734 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Huber | Director | 2026-01-06 | D | 135 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Huber | Director | 2026-01-06 | D | 99 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Huber | Director | 2026-01-06 | D | 26,713 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alejandra Carvajal | SVP, Chief Legal Officer | 2026-01-06 | D | 2,166 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alejandra Carvajal | SVP, Chief Legal Officer | 2026-01-06 | D | 1,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alejandra Carvajal | SVP, Chief Legal Officer | 2026-01-06 | D | 100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kristen Hege | Director | 2026-01-06 | D | 146 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kristen Hege | Director | 2026-01-06 | D | 734 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kristen Hege | Director | 2026-01-06 | D | 2,460 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hack Andrew A. F. | Director | 2026-01-06 | D | 368 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hack Andrew A. F. | Director | 2026-01-06 | D | 1,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hack Andrew A. F. | Director | 2026-01-06 | D | 400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hack Andrew A. F. | Director | 2026-01-06 | D | 346,545 | — | — | Common, indirect | Form 4 ↗ |
| Mohan Bala | SVP, Chief Development | 2026-01-06 | D | 700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mohan Bala | SVP, Chief Development | 2026-01-06 | D | 1,190 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hack Andrew A. F. | Director | 2026-01-06 | D | 118 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian DeSchuytner | SVP, COO & CFO | 2026-01-06 | D | 2,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian DeSchuytner | SVP, COO & CFO | 2026-01-06 | D | 1,750 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian DeSchuytner | SVP, COO & CFO | 2026-01-06 | D | 1,077 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian DeSchuytner | SVP, COO & CFO | 2026-01-06 | D | 4,172 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian DeSchuytner | SVP, COO & CFO | 2026-01-06 | D | 2,671 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian DeSchuytner | SVP, COO & CFO | 2026-01-06 | D | 3,515 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Timothy Lowinger | SVP, Chief Sci.&Tech. Officer | 2026-01-06 | D | 1,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-01-06 | D | 18 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-01-06 | D | 8,137 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anna Protopapas | Director | 2026-01-06 | D | 7,519 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alejandra Carvajal | SVP, Chief Legal Officer | 2026-01-06 | D | 1,527 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alejandra Carvajal | SVP, Chief Legal Officer | 2026-01-06 | D | 3,131 | — | — | Common | Form 4 ↗ |
| Lawrence M. Alleva | Director | 2026-01-06 | D | 544 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence M. Alleva | Director | 2026-01-06 | D | 358 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence M. Alleva | Director | 2026-01-06 | D | 734 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence M. Alleva | Director | 2026-01-06 | D | 181 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence M. Alleva | Director | 2026-01-06 | D | 1,800 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence M. Alleva | Director | 2026-01-06 | D | 546 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence M. Alleva | Director | 2026-01-06 | D | 1,002 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence M. Alleva | Director | 2026-01-06 | D | 133 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence M. Alleva | Director | 2026-01-06 | D | 400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence M. Alleva | Director | 2026-01-06 | D | 84 | — | — | Common | Form 4 ↗ |
| David Mott | Director | 2026-01-06 | D | 2,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Mott | Director | 2026-01-06 | D | 734 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Mott | Director | 2026-01-06 | D | 400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mohan Bala | SVP, Chief Development | 2026-01-06 | D | 1,053 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence M. Alleva | Director | 2026-01-06 | D | 578 | — | — | Common | Form 4 ↗ |
| Michael Huber | Director | 2026-01-06 | D | 9,573 | — | — | Common | Form 4 ↗ |
| Kristen Hege | Director | 2026-01-06 | D | 2,088 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ashish Mandelia | VP, Chief Accounting Officer | 2026-01-06 | D | 1,157 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alejandra Carvajal | SVP, Chief Legal Officer | 2026-01-06 | D | 4,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Allene M. Diaz | Director | 2026-01-06 | D | 1,800 | — | — | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (249 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Michael Huber. DEF 14A, filed 2025-04-29. Section “2024 Summary Compensation Table” · page 43. As printed: 1,613,754. View filing ↗
- Section 01, Brian DeSchuytner. DEF 14A, filed 2025-04-29. Section “2024 Summary Compensation Table”. As printed: 1,543,586. View filing ↗
- Section 01, Mohan Bala. DEF 14A, filed 2025-04-29. Section “2024 Summary Compensation Table”. As printed: 1,502,936. View filing ↗
- Section 01, Timothy Lowinger. DEF 14A, filed 2025-04-29. Section “2024 Summary Compensation Table”. As printed: 1,400,535. View filing ↗
- Section 01, Alejandra Carvajal. DEF 14A, filed 2025-04-29. Section “2024 Summary Compensation Table”. As printed: 1,359,885. View filing ↗
- Section 03, Brian DeSchuytner OPTION. DEF 14A, filed 2025-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Mohan Bala RSU. DEF 14A, filed 2025-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Alejandra Carvajal RSU. DEF 14A, filed 2025-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Huber RSU. DEF 14A, filed 2025-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Timothy Lowinger RSU. DEF 14A, filed 2025-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Brian DeSchuytner RSU. DEF 14A, filed 2025-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Alejandra Carvajal OPTION. DEF 14A, filed 2025-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Timothy Lowinger OPTION. DEF 14A, filed 2025-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Huber OPTION. DEF 14A, filed 2025-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Mohan Bala OPTION. DEF 14A, filed 2025-04-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2025-04-29. Section “CEO Pay Ratio”. As printed: 5 : 1. View filing ↗
- Section 08, David Mott. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 185,996. View filing ↗
- Section 08, Lawrence M. Alleva. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 164,996. View filing ↗
- Section 08, Willard Dere, M.D. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 161,496. View filing ↗
- Section 08, Kristen M. Hege, M.D. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 154,996. View filing ↗
- Section 08, Andrew A. F. Hack, M.D., Ph.D. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 153,496. View filing ↗
- Section 08, Allene M. Diaz. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 150,996. View filing ↗
- Section 08, Anna Protopapas. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 145,996. View filing ↗
- Section 08, Martin Huber, M.D. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, David Mott 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Mott 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Lowinger 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Lowinger 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Mott 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashish Mandelia 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashish Mandelia 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashish Mandelia 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence M. Alleva 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence M. Alleva 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashish Mandelia 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashish Mandelia 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Huber 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence M. Alleva 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence M. Alleva 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mohan Bala 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence M. Alleva 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mohan Bala 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mohan Bala 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alejandra Carvajal 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alejandra Carvajal 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alejandra Carvajal 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Willard H. Dere 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Willard H. Dere 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Willard H. Dere 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Willard H. Dere 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Willard H. Dere 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Willard H. Dere 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Willard H. Dere 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Willard H. Dere 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Willard H. Dere 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Willard H. Dere 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allene M. Diaz 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristen Hege 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristen Hege 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristen Hege 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristen Hege 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristen Hege 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristen Hege 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristen Hege 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hack Andrew A. F. 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hack Andrew A. F. 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hack Andrew A. F. 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hack Andrew A. F. 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hack Andrew A. F. 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian DeSchuytner 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Lowinger 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Lowinger 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Lowinger 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashish Mandelia 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashish Mandelia 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Huber 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence M. Alleva 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alejandra Carvajal 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Willard H. Dere 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristen Hege 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristen Hege 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hack Andrew A. F. 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mohan Bala 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Willard H. Dere 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hack Andrew A. F. 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian DeSchuytner 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian DeSchuytner 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian DeSchuytner 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian DeSchuytner 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian DeSchuytner 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian DeSchuytner 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian DeSchuytner 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Mott 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Lowinger 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashish Mandelia 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashish Mandelia 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Huber 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Huber 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Huber 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Huber 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Huber 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Huber 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Huber 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence M. Alleva 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence M. Alleva 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence M. Alleva 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence M. Alleva 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence M. Alleva 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashish Mandelia 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence M. Alleva 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence M. Alleva 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashish Mandelia 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashish Mandelia 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mohan Bala 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mohan Bala 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mohan Bala 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristen Hege 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristen Hege 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Willard H. Dere 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allene M. Diaz 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allene M. Diaz 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allene M. Diaz 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allene M. Diaz 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allene M. Diaz 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristen Hege 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristen Hege 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian DeSchuytner 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hack Andrew A. F. 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Lowinger 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Lowinger 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Lowinger 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Lowinger 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Lowinger 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Lowinger 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alejandra Carvajal 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alejandra Carvajal 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Mott 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashish Mandelia 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Huber 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Huber 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mohan Bala 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristen Hege 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian DeSchuytner 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian DeSchuytner 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian DeSchuytner 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian DeSchuytner 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Mott 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Mott 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Mott 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Mott 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Mott 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Lowinger 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Lowinger 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashish Mandelia 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashish Mandelia 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashish Mandelia 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Huber 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Huber 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Huber 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Huber 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Huber 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Huber 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alejandra Carvajal 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alejandra Carvajal 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alejandra Carvajal 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristen Hege 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristen Hege 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristen Hege 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hack Andrew A. F. 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hack Andrew A. F. 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hack Andrew A. F. 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hack Andrew A. F. 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mohan Bala 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mohan Bala 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hack Andrew A. F. 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian DeSchuytner 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian DeSchuytner 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian DeSchuytner 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian DeSchuytner 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian DeSchuytner 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian DeSchuytner 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Lowinger 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anna Protopapas 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alejandra Carvajal 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alejandra Carvajal 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence M. Alleva 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence M. Alleva 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence M. Alleva 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence M. Alleva 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence M. Alleva 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence M. Alleva 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence M. Alleva 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence M. Alleva 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence M. Alleva 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence M. Alleva 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Mott 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Mott 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Mott 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mohan Bala 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence M. Alleva 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Huber 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristen Hege 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ashish Mandelia 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alejandra Carvajal 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Allene M. Diaz 2026-01-06. Form 4, filed 2026-01-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 376,000 + equity 0 + all other 0 = 376,000, summed across the director compensation table rows.
- Vor Biopharma, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Vor Biopharma, Inc.'s own proxy. As printed: 65,027,569. View filing ↗
- Scholar Rock Holding Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Scholar Rock Holding Corporation's own proxy. As printed: 33,300,927. View filing ↗
- Zymeworks, Inc., Section 10b CEO total. DEF 14A, filed 2026-10-26. CEO total compensation as printed in Zymeworks, Inc.'s own proxy. As printed: 6,613,180. View filing ↗
- iTeos Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in iTeos Therapeutics, Inc.'s own proxy. As printed: 6,085,657. View filing ↗
- Monte Rosa Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Monte Rosa Therapeutics, Inc.'s own proxy. As printed: 5,032,728. View filing ↗
- CytomX Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in CytomX Therapeutics, Inc.'s own proxy. As printed: 4,738,495. View filing ↗
- IGM Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in IGM Biosciences, Inc.'s own proxy. As printed: 3,207,328. View filing ↗
- C4 Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in C4 Therapeutics, Inc.'s own proxy. As printed: 2,940,975. View filing ↗
- Tango Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Tango Therapeutics, Inc.'s own proxy. As printed: 2,823,992. View filing ↗
- TScan Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in TScan Therapeutics, Inc.'s own proxy. As printed: 2,801,450. View filing ↗
- Werewolf Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Werewolf Therapeutics, Inc.'s own proxy. As printed: 2,545,599. View filing ↗
- Foghorn Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Foghorn Therapeutics, Inc.'s own proxy. As printed: 2,361,027. View filing ↗
- Verastem, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Verastem, Inc.'s own proxy. As printed: 2,349,975. View filing ↗
- Fate Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Fate Therapeutics, Inc.'s own proxy. As printed: 2,248,568. View filing ↗
- Black Diamond Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Black Diamond Therapeutics, Inc.'s own proxy. As printed: 2,234,919. View filing ↗
- Mersana Therapeutics (subject), Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Mersana Therapeutics's own proxy. As printed: 1,613,754. View filing ↗
- Inovio Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Inovio Pharmaceuticals, Inc.'s own proxy. As printed: 1,587,155. View filing ↗
- Adicet Bio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Adicet Bio, Inc.'s own proxy. As printed: 1,465,747. View filing ↗
- Prelude Therapeutics Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Prelude Therapeutics Incorporated's own proxy. As printed: 1,348,000. View filing ↗
- Cue Biopharma, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-16. CEO total compensation as printed in Cue Biopharma, Inc.'s own proxy. As printed: 1,185,639. View filing ↗
- Century Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Century Therapeutics, Inc.'s own proxy. As printed: 912,320. View filing ↗
- Section 10a, CytomX Therapeutics, Inc. reciprocity. DEF 14A. CytomX Therapeutics, Inc. names Mersana Therapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗